Contact Us or Call (913) 647-8000 To See If You Qualify for a Treatment Trial in MS!
Seventeen (17) medications are currently approved by the FDA for modification of the MS disease process. The Rowe Neurology Institute, by participating in over 75 MS therapy trials, has been a part of the approval process for many of these medications for more than 2 decades. So why do we need more MS therapies? Why perform more clinical trials in MS?
Because as effective as the approved medications are, none of them is perfect. Despite hundreds of trials so far, a cure for MS has not been found. Many of the approved drugs are simply re-purposed from the treatment of other diseases and adapted for MS therapy. They address mainly the inflammatory part of the MS disease process.
To date, little headway has been made to promote nerve cell regeneration and re-myelination, two steps critical for recovery from the damage MS does to the nervous system. And the role of the gut and its microbiome in the immune system is just now being investigated, as is the role of hypermobility syndromes on dis-immune states.
Over the years we at the RNI have developed innovative therapies for MS still in use today. Our discoveries have been applied to other diseases, including changes to an X-ray dye that causes kidney damage, when used by cardiologists, neurologists, and radiologists. This new dye has completed Phase I trials outside our institute. And methotrexate, patented for use in MS by our foundation, is still used in some centers to rescue appropriate patients who fail other approved therapies for MS.
We at the RNI are encouraged that breakthroughs in neuro-degeneration and re-myelination are just around the corner. We continue to do basic and clinical research, in cooperation with MS Neurologists in the Kansas City region and nationally, so that patients with MS, and their families as well, will be able to improve the quality of their lives.
Currently Enrolling for the Studies Below:
Click Below For More Information:
- Relapsing Forms of MS—A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (RRMS and SPMS)
- Progressive Forms of MS-–A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacyof Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (SPMS and PPMS)
- Worsening Relapsing Forms of MS—Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) (POINT)
- Advancing RMS Forms of MS Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated oral Siponimod in Advancing RMS Patients. (EXCHANGE)
- Relapsing Forms of MS Study of Evobrutinib in Patients With Relapsing Multiple Sclerosis (EVOLUTION MS2)